What is Revero?
Revero operates at the intersection of health-tech and clinical nutrition, offering a virtual-first clinic designed to address the root causes of chronic illness. The platform utilizes proprietary AI algorithms to analyze patient biomarkers, enabling the delivery of highly personalized nutritional therapy. By integrating digital tools with clinical oversight, Revero aims to eliminate dietary triggers that contribute to disease pathways, thereby improving long-term clinical outcomes. Its market position is defined by its ability to scale personalized care, moving beyond generic wellness advice to provide evidence-based, actionable medical interventions that address systemic health issues.
How much funding has Revero raised?
Revero has raised a total of $5M across 1 funding round:
Angel/Seed
$5M
Angel/Seed (2022): $5M with participation from A16Z Scout, Goodwater Capital, Think + Ventures, and CapitalX
Key Investors in Revero
Goodwater Capital
Goodwater Capital is a consumer tech investment firm that empowers exceptional entrepreneurs to create positive change in the world. They focus on investing in innovative companies across various sectors, including financial services, retail, and healthcare.
Think + Ventures
Think+ is an early stage venture capital firm. It provides financial services or funds to small, early-stage and emerging firms. The company is based in Palo Alto, California.
CapitalX
CapitalX is a company that operates in the Restaurants industry. It employs 10to19 people and has 5Mto10M of revenue. The company is headquartered in Singapore, Central Singapore, Singapore.
What's next for Revero?
With this major enterprise-level funding, Revero is well-positioned to accelerate its product development and expand its clinical reach. The strategic roadmap likely involves enhancing its machine learning capabilities to refine treatment personalization and deepening its integration with existing healthcare ecosystems. As the company scales, the focus will shift toward demonstrating long-term efficacy through clinical outcomes, which will be essential for securing future partnerships with health systems and insurance providers. The current capital injection provides the necessary runway to solidify its market presence and continue its mission of transforming chronic disease management through technology-enabled, patient-centric care.
See full Revero company page
